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Abstract
Gerodermia osteodysplastica (GO) is characterized by skin laxity and early-onset osteopo-
rosis. GORAB, the responsible disease gene, encodes a small Golgi protein of poorly char-
acterized function. To circumvent neonatal lethality of the GorabNull full knockout, Gorab
was conditionally inactivated in mesenchymal progenitor cells (Prx1-cre), pre-osteoblasts
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(Runx2-cre), and late osteoblasts/osteocytes (Dmp1-cre), respectively. While in all three
lines a reduction in trabecular bone density was evident, only GorabPrx1 and GorabRunx2
mutants showed dramatically thinned, porous cortical bone and spontaneous fractures.
Collagen fibrils in the skin of GorabNull mutants and in bone of GorabPrx1 mutants were disor-
ganized, which was also seen in a bone biopsy from a GO patient. Measurement of glycos-
aminoglycan contents revealed a reduction of dermatan sulfate levels in skin and cartilage
from GorabNull mutants. In bone from GorabPrx1 mutants total glycosaminoglycan levels and
the relative percentage of dermatan sulfate were both strongly diminished. Accordingly, the
proteoglycans biglycan and decorin showed reduced glycanation. Also in cultured GORAB-
deficient fibroblasts reduced decorin glycanation was evident. The Golgi compartment of
these cells showed an accumulation of decorin, but reduced signals for dermatan sulfate.
Moreover, we found elevated activation of TGF-β in GorabPrx1 bone tissue leading to
enhanced downstream signalling, which was reproduced in GORAB-deficient fibroblasts.
Our data suggest that the loss of Gorab primarily perturbs pre-osteoblasts. GO may be
regarded as a congenital disorder of glycosylation affecting proteoglycan synthesis due to
delayed transport and impaired posttranslational modification in the Golgi compartment.
Author summary
Gerodermia osteodysplastica (GO) is segmental progeroid disorder affecting connective
tissues and bone, leading to extreme bone fragility. The cause are loss-of-function muta-
tions in the Golgi protein GORAB, whose function has been only partially unravelled.
Using several mouse models and patient-derived primary cells we elucidate that loss of
Gorab elicits a defect in proteoglycan glycanation, which is associated with collagen disor-
ganization in dermis and bone. We also found evidence for TGF-β upregulation and
enhanced downstream signalling. If these changes occur in mesenchymal stem cells or
early osteoblasts they impair osteoblast differentiation resulting in cortical thinning and
spontaneous fractures. We thus match GO mechanistically with also phenotypically over-
lapping progeroid connective tissue disorders with glycanation defects.
Introduction
Bone mass is highly heritable and largely determined by bone growth during childhood and
adolescence leading to the so-called peak bone mass, and the rate of subsequent bone loss at
older ages [1]. Gerodermia osteodysplastica (GO; OMIM #231070) belongs to the group of
autosomal recessive cutis laxa (ARCL) syndromes characterized by lax, wrinkled skin, a gener-
alized connective tissue weakness, and a progeroid appearance [2–4]. GO features pronounced
osteoporosis leading to pathological fractures already in childhood. GORAB, the gene product
defective in GO, is a coiled-coil containing peripheral membrane protein that is recruited to
the Golgi compartment via a specific, GTP-dependent interaction with the small GTPases
ARF5 and RAB6 [5]. Due to this fact, GORAB has been suggested to belong to the group of
golgins, small GTPase effector proteins involved in different steps of Golgi-related transport
processes. Nevertheless, the physiological role or GORAB in development and homeostasis of
the skeleton and of connective tissues is not well understood.
The Golgi compartment is a central hub for protein trafficking and posttranslational modi-
fication within the secretory pathway, among which glycosylation processes are most
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prominent [6]. While the classical disorders of glycosylation (CDGs) affect N-glycosylation
leading to a prototypical combination of neurological, hepatic, and gastrointestinal symptoms,
impairment of the different types of O-glycosylation often causes musculoskeletal phenotypes
[7]. Glycosaminoglycans (GAGs), mostly attached to proteoglycan core proteins through gly-
canation processes in the Golgi apparatus, importantly contribute not only to tissue elasticity
and organization of the ECM, but also regulate growth factor signaling [6]. One example are
the small leucine rich proteoglycans decorin and biglycan, which carry dermatan or chondroi-
tin sulfate GAG chains and regulate collagen fibrillogenesis and signaling mediated by diverse
ligands [8]. Several known disorders of GAG synthesis are characterized by a prematurely
aged appearance and fragile bones [9–11]. However, the molecular background of these
pathologies has only partially been unraveled.
We here report on the characterization of different constitutive and conditional mouse
models indicating that GO is due to osteoblast dysfunction and that Gorab is most relevant in
early stages of osteoblast differentiation. Gorab inactivation reduces dermatan sulfate levels
and proteoglycan glycanation in skin and bone tissue. Loss of GORAB in fibroblasts leads to
decorin retention and lower GAG levels in the Golgi compartment. Altered proteoglycans are
not only associated with disorganization of the collagen matrix, but also with aberrant TGF-β
activation, which likely perturbs differentiation and function of osteoblast lineage cells.
Results
Inactivation of Gorab in mesenchymal stem cells or pre-osteoblasts causes
osteopenia and thinning of cortical bone
The majority of GORABmutations found in GO patients lead to a loss of the GORAB protein
[3]. Therefore, we first constitutively inactivated Gorab in a genetrap mouse line and in a com-
plete knockout after removing the floxed exons 2 and 3 from the Gorabflox locus in the germline
to study the unknown cause for bone fragility in GO (S1A–S1D Fig). Both mouse lines, which
are in the following referred to as GorabNull, showed an identical phenotype with absence of
skin changes reminiscent of cutis laxa, but early lethality due to respiratory distress, most likely
secondary to decreased alveolar airspace (S2A–S2D Fig). This is in line with an independent
description of GorabNull mice [12]. Apart from enlarged fontanels no significant skeletal abnor-
malities were identified (S3A–S3E Fig). Especially the cortical bone porosity was in the normal
range for this developmental stage (S3C and S3D Fig). We took advantage of the β-galactosi-
dase expressed from the Gorab genetrap locus to visualize the expression pattern in the develop-
ing skeleton since available Gorab antibodies lack specificity in immunohistology (Fig 1A).
Strongest signals were seen in the perichondrium and the periosteum, which governs formation
of the cortical bone. Furthermore, we assessed Gorab expression in comparison to several
marker genes in calvarial osteoblasts differentiated in vitro for 12 days until Dmp1, a marker for
late osteoblasts/osteocytes, was robustly expressed (S4A Fig). Gorab expression peaked at day 6
of differentiation, together with type 1 collagen (Col1a1) and decorin (DCN), which was
induced about 40-fold compared to day 0 (S4A Fig). We also differentiated osteoblast precur-
sors isolated from E18.5 and P0 GorabNull calvariae into mineralizing osteoblasts in vitro. Nei-
ther alkaline phosphatase activity nor mineralization as measured by alizarin red showed any
differences correlating with the dramatic bone changes found in GO (S3G and S3H Fig). We
therefore hypothesized that development of the bone phenotype in our murine GO model
occurs mainly postnatally when the embryonic woven bone is converted into mature lamellar
bone, a process which is not faithfully recapitulated in the usual 2D osteoblast cultures.
To investigate the role of Gorab in postnatal skeletal development we generated conditional
Gorabflox mice to selectively prevent Gorab expression in bone tissue while preserving
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expression in the lung (S1C and S1D Fig). We inactivated the gene in the limb bud mesen-
chyme, pre-osteoblasts, and late osteoblasts/osteocytes by crossing Gorabflox mice with Prx1-,
Runx2-, and Dmp1-cre mice, respectively, to investigate at which differentiation stage osteo-
blast lineage cells are most sensitive to a loss of Gorab (S4A Fig) [13–15]. Gorab expression in
cortical bone was reduced to a similar degree in all three conditional mouse lines (S4B Fig).
The resulting GorabPrx1 and GorabRunx2 mutants showed a retardation of long bone growth
and a dramatic loss of cortical and trabecular bone (Fig 1B–1D). In contrast, only a mild loss
of trabecular bone was evident in tibiae from GorabDmp1 mutants (Fig 1B–1D) (S5A Fig).
Since Prx1 is not expressed in the axial skeleton no changes were observed in GorabPrx1 verte-
bral bone structure, but GorabRunx2 and GorabDmp1 mutants showed a clear vertebral osteope-
nia (S5B Fig). These data suggest that, at least for cortical bone development, Gorab function
Fig 1. Gorab conditional inactivation in mesenchymal progenitors and pre-osteoblasts, but not at later stages leads to severe cortical
bone thinning. (A) Gorab expression in chondrocytes, perichondrium (red arrowhead), and periosteum (black arrowhead) as indicated by
LacZ staining of E18.5 GorabNull tibia. Scale bar = 50μm. (B) Sagittal view and (C) transverse view of reconstructed μCT image of tibia from
twelve week old GorabPrx1, GorabRunx2, GorabDmp1 and control animals. (D) Quantitative μCT analysis given as fold changes for trabecular
bone volume (BV/TV), length and cortical thickness (Cort.Th), of tibia of twelve week old GorabPrx1 (N = 15), GorabRunx2 (N = 5),
GorabDmp1 (N = 8) and littermate control animals, N = 14, N = 5 and N = 9 for each individual conditional mouse line, respectively. Values
were normalized to the control littermates of each mutant line to facilitate comparison.
https://doi.org/10.1371/journal.pgen.1007242.g001
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is most important during differentiation of pre-osteoblasts from mesenchymal progenitor
cells.
Cortical thinning and porosities result in spontaneous fractures in
GorabPrx1 mutants
We then focused our analysis on the GorabPrx1 model, which corresponded well to the GO
long bone phenotype. The biomechanical and material properties of bone tissue from this
mouse model have been described elsewhere [16]. Histological analysis of different stages of
postnatal development revealed that the bone anomalies were most striking in the tibia at four
weeks of age. Thinning and porosities of the cortical bone were most pronounced in the poste-
rior metaphyses (Fig 2A). Several cells were observed in the large cortical pores suggesting that
they represent merged osteocyte lacunae. The overall number of osteocyte lacunae was ele-
vated and the periosteum was strongly thickened at the expense of cortical bone (Fig 2B). The
metaphyseal cortical bone changes in GorabPrx1 culminated in very high bone fragility as mir-
rored by spontaneous fractures in up to 80% homozygous mutants within the first four weeks
of postnatal development (Fig 2C). Humeri and tibiae were most frequently affected, often
Fig 2. Cortical porosity and osteoblast dysfunction in the GorabPrx1 model recapitulate the gerodermia osteodysplastica bone phenotype. (A) Von Kossa /
hematoxylin stained cortical bone of twelve week old GorabPrx1 mouse. Inset showing magnified view of large pores in the mutant diaphysis. Scale bar = 200 μm. (B)
Sections of metaphyseal cortical bone of the tibia of four week old GorabPrx1 mice stained with Masson Goldner trichrome. Scale bar = 100μm. (C) μCT reconstructed
image of a spontaneously fractured humerus from a four week old GorabPrx1 mouse. Arrowhead = fracture site. Scale bar = 1mm. (D) Histomorphometric quantitation
number of osteoblast per bone perimeter (N.Ob/B.Pm), (E) number of osteocytes per cortical bone perimeter (N.Ot/cort B.Pm). (F) Mineral apposition rate (MAR) at the
endosteum of tibia midshaft in four week old GorabPrx1 (N = 4). Inset showing calcein double labeling, C = control, M = mutant. (G) osteoid volume (OV/TV) in
secondary spongiosa of the proximal tibia in GorabPrx1 mutants vs. controls at four weeks of age (N = 4–6). (H) Altered expression of osteoblast lineage marker genes in
femoral cortical bone of four week old GorabPrx1 mutants (N = 6–8). (I) Immunohistochemical detection of Sp7/osterix, Spp1/osteopontin and Dmp1 expression in
cortical bone. Note higher number of osterix + cells in GorabPrx1 mutants. Scale bar = 50μm. (J) Number of osteoclasts per bone perimeter (N.Oc/B.Pm). (K) Opg to
Rankl expression ratio in four week old GorabPrx1 mutants (N = 6). P = periosteum, C = cortical bone, E = endosteum.
https://doi.org/10.1371/journal.pgen.1007242.g002
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leading to deformations. We postulate that Gorab deficiency in early osteoblast lineage cells
during the first weeks of postnatal development cannot be compensated due to the immense
rate of ECM production, which is known to exert stress on the cells secreting ECM
components.
Altered differentiation and gene expression of osteoblast lineage cells in
GorabPrx1 mutants
We therefore next wanted to know more about the impact of loss of Gorab function on the
cells of the bone multicellular unit. Histomorphometric analysis of GorabPrx1 tibiae revealed
higher osteoblast and osteocyte numbers (Fig 2D and 2E). In spite of more abundant osteo-
blasts, mineral apposition rate was reduced in GorabPrx1 mutants and an increased osteoid sur-
face indicated impaired mineralization (Fig 2F and 2G). A reduced cortical bone mineral to
matrix ratio was also detected in twelve week old GorabPrx1 mutants by Fourier transform
infrared (FTIR) imaging [16]. These findings were confirmed in a bone biopsy from a GO
patient, demonstrating that our mouse model closely recapitulates the human condition (S6
Fig). To elucidate the basis for these osteoblast lineage anomalies we performed expression
analyses in tibial cortical bone tissue. Individual qPCR assessment of osteoblast marker genes
revealed an upregulation of Spp1 and Sp7 (Fig 2H). In addition, genome-wide expression
analysis of GorabPrx1 diaphyseal cortical bone by array hybridization and qPCR verification
showed upregulation of the osteocyte marker genes Dmp1 and Fgf23, (Fig 2H)(S1 Table).
The upregulation of Dmp1 was already evident in E18.5 GorabNull bones, together with a slight
suppression of Sost, which could indicate a delay in osteocyte maturation during prenatal
development (S3F Fig). Immunohistochemistry confirmed increased levels of the proteins
osteopontin, osterix, and dentin matrix protein 1 in GorabPrx1 cortical bone (Fig 2I). Interest-
ingly, also the genes Ank, Enpp1, and Mepe known to inhibit mineralization were induced in
GorabPrx1 mutants (S1 Table), possibly contributing to the observed osteoid mineralization
defect (Fig 2G). With the exception of normal Sost expression levels the gene expression pro-
file in GorabPrx1 mutant cortical bone resembled that of osteoid osteocytes indicating that
terminal osteocyte differentiation was impaired as a consequence of Gorab inactivation in oste-
oblast precursors [17].
Osteoclast numbers were not significantly changed in GorabPrx1 trabecular bone (Fig 2J).
Cell counts in the available human bone biopsy neither did show significantly elevated osteo-
clast numbers (S6 Fig). Although ECM disorganization often induces increased osteoclast
numbers and activity, this is probably suppressed in GorabPrx1 mutants by an elevated Opg/
Rankl ratio detected by expression analysis (Fig 2K) [18, 19]. Taken together, these data sug-
gest low turnover kinetics due to functional impairment of the osteoblast lineage. This is in
contrast to osteogenesis imperfecta (OI), the most common type of congenital bone disease
with fractures, which is characterized by high turnover kinetics [18].
Abnormal collagen fibrillogenesis in Gorab deficient skin and bone tissue
Gerodermia osteodysplastica is characterized by a congenital ligamentous laxity indicating col-
lagen abnormalities, and dermal elastic fiber changes. Investigating the dermis of newborn
GorabNull mice by electron microscopy we found a disorganization of collagen fibers (Fig 3A).
In contrast to control skin almost no fibril formation was seen. Elastic fibers are not yet formed
at this developmental stage and could therefore not be studied. GorabPrx1 cortical bone was
thinner and showed reduced stiffness and increased fragility (Fig 2B)[16]. The mechanical
properties of bone are also determined by collagen organization. Similar to the skin we also
found missing alignment of collagen fibers surrounding the osteocytes in four week old
Gorab glycosylation TGF-β
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GorabPrx1 mutants (Fig 3B). Picrosirius red staining and polarized light microscopy confirmed
globally impaired collagen fibrillogenesis in tibial cortical bone from GorabPrx1 mutants and in
a pelvic bone biopsy from a nine year old GO patient (Fig 3C). Our results show the presence
of impaired collagen fibrillogenesis in GO, at least during development of bone and connective
tissues.
Reduced dermatan sulfate content and impaired proteoglycan glycanation
in Gorab deficient skin and bone tissue
The Golgi localization of GORAB is suggestive of a function in protein secretion and/or modi-
fication. Metabolic labeling of fibroblasts from GO patients showed no influence of GORAB
on global protein or collagen secretion (S7A and S7B Fig). However, collagen and elastic fiber
changes similar to GO were described in other progeroid connective tissue disorders second-
ary to impaired glycanation of proteoglycans [9–11]. To test a possible involvement of proteo-
glycans in GO pathology, we measured glycosaminoglycans (GAGs) in tissues from E18.5
GorabNull embryos. We observed a significant reduction in the amount of dermatan sulfate,
but not of other GAGs in skin and cartilage, indicating a specific defect (Fig 4A)(S7C Fig). In
GorabPrx1 tibial cortical bone the total GAG levels as well as the relative amounts of dermatan
sulfate levels were strongly reduced (Fig 4B and 4C). Biglycan and decorin are major derma-
tan- and chondroitin sulfate-carrying proteoglycans in bone and connective tissues. Their
fully glycanated form can be difficult to detect in immunoblots with tissue lysates due to their
apparent size (decorin 100 kDa, biglycan >200 kDa) and low accessibility of the epitope resid-
ing in the core proteins that have a size of 42 kDa and 45 kDa, respectively. Immunoblot detec-
tion of both proteoglycans in skin tissue lysates showed a partial loss of the fully glycanated
forms and stronger core protein bands in GorabNull mutants suggesting absent/shortened
GAG chains (Fig 4D)(S7D Fig). Furthermore, after treatment with chondroitinase ABC the
core proteins of decorin and biglycan both gave stronger signals indicating lesser glycanation
Fig 3. Disrupted collagen network in skin and bone tissue deficient for Gorab. (A) Electron microscopy of skin from E18.5 GorabNull mouse
(magnification = 11700x) and (B) bone from tibia of eight week old GorabPrx1 mouse. Asterisk marks collagen fibers, Ot = osteocyte. (C) Collagen
fiber orientation in cortical bone of four week old GorabPrx1 mutants and in a GO patient bone biopsy stained with picrosirius red or toluidine blue,
respectively, and imaged under polarized light. Note fragmentation of birefringence signals. For each experiment at least N = 3 mice were analyzed,
representative images are shown.
https://doi.org/10.1371/journal.pgen.1007242.g003
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(S7E and S7F Fig). No upregulation of mRNA expression was detected, which could alter-
natively explain the stronger core protein bands (S7G and S7H Fig). Also in bone lysates
from four week old GorabPrx1 animals the fully glycanated form of decorin was less abundant
compared to littermate controls and bands with lower apparent weight were enhanced (Fig
4E). Reduced decorin glycanation has been demonstrated to be a consequence of aging in
human skin [20]. We found a similar reduction in decorin glycanation with aging in cortical
bone from wildtype mice (Fig 4F). Decorin glycanation in 4 week old GorabPrx1 bone was
reduced to a level similar to that of 26 week old controls (compare Fig 4E and 4F). Taken
together, loss of Gorab caused a general reduction of proteoglycan glycanation, exemplified by
the changes in glycanation status of decorin and biglycan, similar to that found in the aged
ECM.
Decorin and biglycan play a vital role in collagen fibrillogenesis [21], are highly expressed
in osteoblasts (S4A Fig) and were linked to alterations of matrix mineralization, growth factor
signaling, and bone fragility [22–25]. In immunohistology we found enhanced signals for
biglycan and decorin in the ECM of the thickened periosteum in GorabPrx1 tibiae, most likely
due to enhanced accessibility of the epitope as a consequence of lower glycanation (Fig 4G
Fig 4. Loss of Gorab resulted in underglycanation of proteoglycans. (A) Quantitation of dermatan sulfate and chondroitin sulfate in skin, cartilage, and lung
samples from E18.5 GorabNull mice (N = 3–4). (B) Total amount of GAGs in the cortical bone of femora from four week old GorabPrx1 mutants and littermate controls
(N = 3–4). (C) Percentage of dermatan sulfate in the total amount of glycosaminoglycans (GAGs). (D) Immunoblotting for decorin in skin samples from E18.5
GorabNull mice. Loss of the 100kDa band, corresponding to the fully glycanated decorin, and higher intensity the core protein band in mutant lysate indicate a
glycanation defect. (E) Immunoblotting for decorin in cortical bone lysates from four week old GorabPrx1 mice and littermate controls also showing higher intensity of
lower bands in mutant. (F) Immunoblot of decorin in cortical bone lysates from wildtype (WT) mice at different ages: newborn (P0), 5 weeks (5W), 26 weeks (26W)
and 2 years (2Y). Note reduction in glycanation with increasing age. (G) Immunofluorescence detection of decorin and (H) biglycan in tibia of four week old
GorabPrx1 mice. Sections were not pretreated with chondroitinase. Higher staining intensities therefore indicate lower glycanation of the core proteins in the
periosteum. P = periosteum, C = cortical bone. Scale bar = 50μm. Experiments (D) to (H) were repeated at least three times with independent biological samples,
representative results are shown.
https://doi.org/10.1371/journal.pgen.1007242.g004
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and 4H). This suggested a role of these pathologically glycanated proteoglycans in the abnor-
mal gain of periosteum thickness.
GORAB deficiency in fibroblasts leads to reduced glycanation and
accumulation of decorin in the Golgi compartment
In order to investigate whether the observed proteoglycan abnormalities are due to a perturba-
tion of the producing cells we investigated decorin production in cultured fibroblasts. In
lysates from confluent GorabNull and control fibroblasts we observed a downward shift of the
band corresponding to the glycanated form (Fig 5A). A similar finding was obtained for bigly-
can (S7E Fig). Also decorin secreted by fibroblasts from GO patients displayed a significant
reduction of the fully glycanated form (Fig 5B). These data demonstrate that the reduced gly-
canation of proteoglycans in Gorab-deficient mouse mutants can be recapitulated in vitro in
both mouse and human fibroblast cell lines.
The GORAB protein is associated with the medial/trans Golgi compartment, where it sup-
posedly regulates transport processes [5]. Therefore, we hypothesized that the decorin abnor-
malities could be due to impaired intracellular trafficking. In order to prevent influence of
extrinsic factors and to ensure comparable immunofluorescence stainings, the following
experiments were done in co-cultures of fibroblasts derived from control and GO individuals.
Both cell types could be distinguished by presence or absence of GORAB immunofluorescence
staining (Fig 5C). GORAB-deficient cells showed increased co-localization of decorin and the
Golgi marker GM130 in immunofluorescence compared to GORAB-expressing control cells
(Fig 5C). We also assessed the dermatan sulfate levels at the Golgi compartment detected by
antibody GD3A12 through immunofluorescence co-staining with the Golgi marker TGN46
[26]. Although decorin accumulated at the Golgi compartment, the signals for dermatan sul-
fate chains were less intense (Fig 5D). Thus, loss of GORAB seems not only to reduce antero-
grade trafficking of decorin within the Golgi, but also dermatan sulfate attachment to its core
protein. Given the abovementioned changes in total GAG levels in bone and in biglycan glyca-
nation (S7F Fig), this effect does not seem to be limited to decorin, but probably affects proteo-
glycans in general.
Enhanced TGF-β activation and downstream signaling
Besides collagen, decorin and biglycan also bind TGF-β with high affinity and modulate its
bioavailability and interaction with receptors [27, 28]. TGF-β is a central regulator of bone
remodeling produced by osteoblasts. It is secreted predominantly in its latent, inactive form
and deposited into the matrix from where it gets activated by osteoclast activity and proteolytic
cleavage [29, 30]. Excessive TGF-β signaling has been shown to be crucial in the pathology of
osteogenesis imperfecta and several connective tissue disorders [19, 31]. Using a TGF-β
reporter cell line, we found an increase of active TGF-β in GorabNull skin lysates, while total
TGF-β levels remained constant (Fig 6A). Evidence for elevated TGF-β signaling was also indi-
cated by the upregulation of TGF-β responsive genes such as Serpine1 in cortical bone of Gor-
abPrx1 mutants (Fig 6B). Increased nuclear staining of p-Smad2 was found in GorabPrx1 bone
tissue, in particular in cells located in the enlarged periosteum (Fig 6C), indicating activation
of TGF-β signaling in osteoblast lineage cells. In low passage (5–10) GO skin fibroblasts we
also observed increased levels of p-SMAD2, and elevated expression of TGF-β responsive
genes (Fig 6D and 6E). These findings suggest that GO can be regarded as a congenital disor-
der of glycosylation (CDG) leading to a disorganized collagen network and TGF-β activation
due to abnormal function of the underglycanated proteoglycans, including decorin and
biglycan.
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Discussion
Our results suggest that the loss of Gorab in the Golgi compartment causes reduced proteogly-
can glycanation, abnormalities in collagen networks, and subsequent TGF-β overactivation.
GAGs are essential for the function of proteoglycans. This is highlighted by several congenital
disorders of glycosylation (CDGs) caused by deficient attachment of GAGs to the proteoglycan
core protein in the Golgi compartment [9–11]. Besides generalized connective tissue problems
and a progeroid appearance some of these disorders also show a dramatic bone fragility. In
contrast to GO, these disorders are readily classified as CDGs since they affect enzymes
involved in GAG synthesis. The typical readout used in functional studies for these disorders
Fig 5. Golgi retention and reduced glycanation of decorin in Gorab-deficient fibroblasts. (A) Western blot analysis of decorin in control and GorabNull MEF cell
lysates. The size ranges for the fully glycanated form of decorin (DCN) and of its core protein are indicated. (B) Left, western blot analysis of decorin in lysates of the
extracellular matrix produced by cultured control and GO fibroblasts. Right, levels of glycanated decorin were quantified against total decorin levels (N = 3). (C) Analysis
of intra-Golgi levels of decorin in co-cultured control and GO human skin fibroblasts. Immunofluorescence labeling was performed with anti-decorin, anti-GORAB and
anti-GM130 antibodies. GORAB staining was used to distinguish control (yellow arrows) and GO (red arrows) cells. Decorin fluorescence intensity in both cell types was
normalized against that of the Golgi marker GM130 (N = 3,>500 cells analyzed per cell line). Scale bar = 10 μm. (D) Analysis of intra-Golgi levels of dermatan sulfate
(DS)-modified proteins in co-cultured control (yellow arrows) and GO (red arrows) human skin fibroblasts. Cells were labeled with anti-DS (GD3A12), anti-GORAB
and anti-TGN46 antibodies. The intensity of the GD3A12 fluorescence signals were measured relative to that of the Golgi marker TGN46 (N = 3,>500 cells analyzed per
cell line). Scale bar = 10 μm.
https://doi.org/10.1371/journal.pgen.1007242.g005
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is decorin glycanation status [32]. Our data imply a strong clinical and biochemical overlap of
these disorders with GO and suggest that GO might be regarded as a CDG.
We used different cre-expressing mouse lines to learn more about the stage of osteoblast
differentiation at which Gorab is most essential. Gorab expression peaks in mature osteoblasts,
together with ECM proteins like type 1 collagen. It seems that only a loss of Gorab expression
before this osteoblast differentiation stage in GorabPrx1 and GorabRunx2 mice gives rise to the
full phenotypic picture, while deletion in late osteoblasts in the GorabDmp1 line has milder
effects. Late osteoblasts are characterized by reduced ECM production and start to convert
into osteocytes [17]. Likewise, the GorabPrx1 and GorabRunx2 mouse models develop age-
related phenomena like cortical porosity and low bone turnover already during bone growth,
thus hampering bone mass accrual. We speculate that the reason for this might be the strong
ECM production during the postnatal growth spurt. From these aspects we conclude that loss
of GORAB primarily perturbs strongly ECM secreting cells, which might explain the selective
affection of bone and connective tissues in GO in spite of the ubiquitous expression of
GORAB.
The small leucine-rich proteoglycans (SLRPs) are important for ECM homeostasis by regu-
lating collagen fibrillogenesis and binding to TGF-β and other ligands and receptors in a com-
plex manner [8]. It has been hypothesized that upon alteration of the collagen network SLRP
binding to the ECM is loosened leading to increased release of active TGF-β [19]. Diffusible
Fig 6. Elevated TGF-β signaling in Gorab-deficient skin, bone, and fibroblasts. (A) Quantitation of active and total
TGF-β in skin lysates from E18.5 GorabNull mice (N = 3). (B) Enhanced expression of TGF-β regulated genes in the
diaphysis of four week old GorabPrx1 mutants (N = 7–8). (C) Immunofluorescence staining for p-SMAD2 in GorabPrx1
mutants and controls at four weeks of age. Representative picture of N = 4 per group. Note stronger signals in periosteum
in mutants. Scale bar = 50μm. (D) Western blot of p-SMAD2 in confluent fibroblasts from GO patients and healthy
controls (N = 3) and quantitative evaluation. (E) Quantitative PCR to measure expression of TGF-β responsive genes in
GO patient-derived fibroblasts (N = 4). P = periosteum, C = cortical bone. E = endosteum.
https://doi.org/10.1371/journal.pgen.1007242.g006
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biglycan and decorin might even enhance binding of TGF-β to its receptor, thereby further
inducing collagen production to repair the defective collagen network [33]. The knockout of
decorin and also the exchange of its GAG-carrying serine residue have only mild phenotypic
effects [34, 35]. In contrast, loss of biglycan leads to osteopenia and cortical thinning quite sim-
ilar to GorabPrx1 and GorabRunx2 mutants [25]. Human biglycan loss-of-function mutations
cause aortic dilatation, malar hypoplasia, and osteopenia with thin cortices, a clinical picture
somewhat reminiscent of GO [36]. Defective decorin glycanation, which we show in aging
bone tissue, has also been demonstrated to be a consequence of skin aging [20]. Generally, the
sulfated GAG content of many tissues is reduced with increasing age [37]. From an evolution-
ary standpoint it was suggested that age-related changes in glycosylation patterns might shield
the organism from cancer by lowering proliferation signals and enhancing differentiation sig-
nals like TGF-β [38]. Binding of biglycan and decorin to TGF-β and to type 1 collagen is medi-
ated by the core protein and can be lowered by the attached GAG chains [39]. On the other
hand, dermatan sulfate was shown to bind to collagen fibrils in a reproducible pattern, which
might explain the observed differences in the binding patterns of glycanated and non-glyca-
nated decorin to collagen fibrils [40, 41]. We therefore assume that reduced glycanation of
SLRPs plays a leading role in the pathogenesis of GO.
In our mouse models and also in cultured cells we found evidence for elevated TGF-β acti-
vation, which we propose to be a consequence of the disrupted ECM. TGF-β signaling plays
pivotal role in bone homeostasis [30]. TGF-β stored in the bone matrix is released and acti-
vated during bone resorption. This is turn attracts bone osteoprogenitor cells to the resorption
sites, which subsequently proliferate and differentiate into osteoblasts, thus coupling bone
resorption to bone formation [29, 42]. A dampening of TGF-β signaling has been shown nec-
essary for terminal osteoblast differentiation [43]. Furthermore, persistently high doses of
TGF-β have been shown to inhibit osteoblast differentiation in a physiologically relevant man-
ner as shown for osteogenesis imperfecta and other disorders of the ECM [19, 31, 44]. Trans-
genic overexpression of TGF-β2 in murine osteoblasts results in osteopenia, cortical thinning,
and elevated osteocyte numbers [45]. Moreover, constitutive overexpression of Sp7/osterix in
osteoblasts causes an accumulation of abnormal osteocytes in the absence of elevated osteoclast
numbers [46]. Both mentioned mouse models phenotypically closely overlap with the Gor-
abPrx1 mutants. Interestingly, a direct upregulation of Sp7/osterix by TGF-β has been demon-
strated [47]. Furthermore, the expression of Dmp1, which is strongly induced in Gorab-
deficient bone tissues, was found to depend on Tcf11, which is also regulated by TGF-β [48,
49]. TGF-β has been demonstrated to promote Rankl-induced osteoclastogenesis [50]. In con-
trast to other models with elevated TGF-β signaling there is no consistent increase in osteoclast
numbers in Gorab-deficient mice [19, 44]. This can be possibly attributed to the elevated Opg/
Rankl ratio in our mouse model. One explanation for this might be the timing of exposure of
osteoblast lineage cells to elevated TGF-β. In fibrillin 1-deficient mice TGF-β signaling is
altered at the level of the stromal mesenchymal stem cell niche, while in GorabPrx1 later stages
of osteoblast differentiation are affected [44].
The localization of GORAB in the medial/trans Golgi is perfectly in line with an
impairment of GAG chain elongation, which is carried out in this compartment [51]. The
function of GORAB interaction partners ARF5, RAB6, and SCYL1 in retrograde Golgi traf-
ficking suggests that the transport of factors relevant for glycanation might be impaired, simi-
lar to the regulation of EXT proteins by the Golgi protein GOLPH3 [3, 5, 52]. Golgi trafficking
defects are often difficult to investigate in vitro. Even in the lethal phenotypes caused by muta-
tions in COG7 or TRIP11, encoding a component of the conserved oligomeric Golgi complex
and the golgin Gmap-210, respectively, only relatively mild abnormalities were found in cul-
tured mutant cells [53, 54]. Only after acute loss of Gmap-210 a global impairment of protein
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secretion and a retrograde trafficking delay became visible [55]. These results together with the
clear glycanation impairment in vivo underline the significance of the proteoglycan alterations
observed in GORAB deficient fibroblasts.
Although multiple lines of evidence point towards a central role of a perturbed proteogly-
can-TGF-β axis in osteoblast lineage dysfunction in GO, it has been described that loss of
Gorab impairs hedgehog signaling leading to reduced hair growth in GorabNull mutants [12].
Although GO patients show no hair phenotype and the bone phenotype is not typical for
altered hedgehog signaling it is possible that this mechanism also contributes to the GO bone
pathology [56]. Interestingly, mice deficient for the golgin Gmap-210 not only had a lung
pathology very similar to GorabNull mutants, but were also reported to show cilia abnormalities
[57]. On the other hand, also knockout of the Golgi enzyme gPapp impairing GAG sulfation
leads to a lung phenotype closely resembling that of GorabNull mutants, which supports our
hypothesis of a GAG-driven pathomechanism [58]. Further studies are needed to disentangle
the contributions of these different pathways.
In summary, our study provides a link between the Golgi compartment, intracellular pro-
teoglycan transport and glycanation, ECM disorganization and porosity, and TGF-β overacti-
vation. Some aspects of this pathomechanism are also seen in chronological bone aging, but
seem to occur already during postnatal growth in GO leading to the progeroid phenotype. The
mechanism described here places GO in close proximity to congenital disorders of glycosyla-
tion with impaired proteoglycan synthesis.
Methods
Ethics statement
Permission for work with human cells was granted by the Charite´ Ethics Committee (approval
number EA2/145/07). We or the referring clinicians obtained oral informed consent from
patients for genetic testing and the use of fibroblasts derived from skin biopsies. Healthy con-
trol individuals also gave written informed consent for use of fibroblasts.
All animal experimental procedures were approved by the Landesamt fu¨r Gesund-
heitsschutz und Technische Sicherheit (LaGeTSi), Berlin, Germany (approval number G0213/
12). Experiments using animal-derived materials were conducted according to the German
law for animal protection (TierSchG).
Animal procedures
All analyses were done on homozygous GorabGt genetrap or Gorab-/- (GorabNull) embryos, or
on female mice homozygous for the conditional Gorabflox allele and heterozygous for the
Prx1-cre transgene (GorabPrx1). Homozygous conditional Gorabflox mice without the cre allele
from the same generation served as controls. All animals had been backcrossed with C57/Bl6
mice for at least 5 times.
Generation of GorabNull mouse model
GorabNull animals were generated using genetrap ES-cell clone XG183 purchased from Bay Geno-
mics, San Francisco, CA, USA. Germline deletion of Gorabflox allele by crossing with CMV-cre
mice resulted in homozygous mutants that were phenotypically identical to GorabNull mice.
Construction of Gorabflox conditional mouse model
The construction strategy was as shown in S1C Fig. A BAC clone containing the mouse
Gorab locus, BAC clone bMQ-373H11 (129S7Ab2.2) was obtained from Geneservice Ltd
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(Cambridge, UK). A ~11.1kb region containing exons 2 to 4 of Gorab and the flanking introns
was extracted into a pBluescript vector by recombination. LoxP sites were inserted into the tar-
geting vector flanking exons 2 and 3 by homologous recombination. Gene targeting of mouse
ES cells was done with the help from the Transgenic Core Facility of The University of Hong
Kong. Correctly targeted clones were identified by Southern blot and injected into blastocysts
from C57BL/6 mice to generate chimeric mice. Mice with germline transmission of the condi-
tional cassette were crossed with ß-actin-flp mice to remove the neomycin selection cassette.
The resulting animals were crossed with Prx1-cre mice to yield GorabPrx1 mutants. Crossing
with CMV-cre mice resulted in Gorab-/- mutants through germline deletion.
microCT analysis
microCT analysis for the GorabPrx1 and GorabDmp1 mutants and corresponding littermate con-
trols were done with Scanco μCT40 (Scanco Medical, Bru¨ttisellen, Switzerland) at 10μm reso-
lution; while GorabRunx2 and littermate controls were analyzed with Skyscan 1172 (Bruker
microCT, Luxemburg, Belgium) at 5μm resolution. Tibiae and vertebra were first fixed in 4%
paraformaldehyde (PFA) in 4˚C for 24 hours then scanned in 70% ethanol at 10μm resolution.
The trabecular bone measurement was done for a region of 700 μm in the secondary spongiosa
of proximal metaphysis of the tibia and the entire vertebral body. 1 mm of cortical bone was
measured at a region 1200 μm below the proximal metaphysis of the tibia.
Histology
E18.5 GorabNull embryos were sacrificed and dissected under PBS for lung biopsies to prevent
collapse of the lung. Samples were then fixed in 4%PFA at 4˚C for 24hours and then dehy-
drated through gradient ethanol from 70%, 80%, 90% and 100% ethanol at 4˚C for 24hours at
each step. The samples were then cleared in xylene twice at room temperature for 15min and
then infiltrated with paraffin for 60 minutes three times followed by embedding. The embed-
ded samples were sectioned and stained with hematoxylin/eosin for histology. Undecalcified
mouse tibiae from E18.5 GorabNull embryos and four week old GorabPrx1 mice were first fixed
in 4% PFA and subsequently embedded in methylmethacrylate, MMA (Cat#00834, Poly-
sciences, Eppelheim, Germany) and sectioned for histological studies. The fixed bone samples
were dehydrated through gradient ethanol from 70%, 80%, 90% to 100% and twice in xylene
for 24h in each step. The samples were then infiltrated with infiltration MMA (1%v/v polyeth-
ylene glycerol (Sigma-Aldrich, Munich, Germany) and 0.33% w/v benzoyl peroxide in MMA)
for at least 24hours at 4˚C. The polymerization was carried out at 4˚C in polymerization solu-
tion (1%v/v polyethylene glycerol, 0.55% w/v benzoyl peroxide, 0.5% v/v N,N-dimethyl-p-
toluidine in MMA). The embedded samples were then sectioned using a Leica RM2255 micro-
tome (Leica, Wetzlar, Germany) at 5 μm thickness and subjected to Von Kossa/Van Giesson
staining, Von Kossa/hematoxylin staining, Goldner trichrome staining or Pircosirius red
staining.
Histomorphometry
Histomorphometric analysis of the secondary spongiosa of proximal tibia of 4 weeks old Gor-
abPrx1 mice was carried out using the software Osteomeasure (Osteometrics, Atlanta, USA).
For mineral apposition rate determination, GorabPrx1 and control animals were injected with
calcein (10μl per gram body weight) at P23 and P26 and sacrificed at P28. The tibiae of the ani-
mals were fixed in 4% PFA and embedded in MMA as mentioned previously and then sec-
tioned at 5μm thickness. The distance between the two lines of calcein labels at the mid bone
shaft was subsequently imaged and measured for mineral apposition rate calculation.
Gorab glycosylation TGF-β
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007242 March 21, 2018 14 / 24
Transmission electron microscopy
All specimens were fixed for at least 2h at room temperature in 3% glutaraldehyde solution in
0.1M cacodylate buffer pH 7.4 and then cut into pieces of 1mm3. The samples were then
washed in buffer and postfixed for 1h at 4˚C in 1% osmium tetroxide, followed by dehydration
through graded ethanol solutions and embedded in epoxy resin (glycidether 100). Semithin
and ultrathin sections were cut with an ultramicrotome (Reichert Ultracut E). Ultrathin sec-
tions were treated with uranyl acetate and lead citrate, and examined with an electron micro-
scope Philips EM 400.
Quantitation of glycosaminoglycans (GAGs) in tissues
GAGs were prepared from E18.5 embryo skin, lung, cartilage and brain as described previously
[59]. Each extract was digested with chondroitinase AC (Seikagaku Corp., Tokyo, Japan), chon-
droitinase B (IBEX Tech., Montreal, Canada), or heparinase (IBEX Tech., Montreal, Canada) for
analyzing the disaccharide composition of CS, DS, or HS, respectively. Each digest was labeled
with a fluorophore 2-aminobenzamide (2-AB) (Nacalai tesque, Kyoto, Japan), and analyzed by
anion-exchange HPLC. To recover GAGs from bone specimens, tibia diaphysis from 4 week old
GorabPrx1 and wildtype mice were decalcified and digested with 20U of papain (Sigma-Aldrich,
Milano, Italy) in 100mM sodium acetate, pH 5.6, 100mM EDTA and 5mM cysteine at 65˚C for
48h. GAGs were purified by cetylpyridinium chloride precipitation and hyaluronic acid was
removed by digestion with Streptomyces hyaluronidase (Seikagaku Corp., Tokyo, Japan) fol-
lowed by ultrafiltration as described previously [60]. For CS and DS disaccharide composition,
GAG aliquots were digested with chondroitinase ABC (AMSBIO, Abingdon, UK) (digesting
chondroitin sulfate A, B and C) or chondroitinase ACII (Seikagaku Corp., Tokyo, Japan) (digest-
ing chondroitin sulfate A and C). Each digest was labeled with 2-aminoacridone (Thermo Fisher
Scientific, MA, USA) and analyzed by reverse phase HPLC as described previously [61]. The der-
matan sulfate (chondroitin sulfate B) fraction was determined as disaccharide fraction undigest-
able by chondroitinase ACII vs. disaccharides digested by chondroitinase ABC.
Immunoblotting and immunostaining
Cell lysates from in vitro cultures were extracted with RIPA buffer followed by sonication.
Mouse tissue samples were pulverized in liquid nitrogen and lysates were extracted with 8M
urea buffer, 1% SDS with sonication. For chondroitinase ABC digestion the buffer was
exchanged to 0.1M Tris-HCl pH8.0 using microcon 10kDa centrifugal filter units and subse-
quently incubated at 37˚C for 18 hours with or without chondroitinase ABC (ABCase, 0.3U/
100μg protein). Mouse bone biopsies were first fixed in 4% PFA and then decalcified in
Morses’ solution (10% Sodium Citrate, 20% Formic Acid). The decalcified bone were then
embedded in paraffin and sectioned for immunostainings. Antibodies used are as follows:
Anti-p-Smad2 (#3101, Cell Signaling, Leiden, The Netherlands), anti-SMAD2 (#3102, Cell Sig-
naling, Leiden, The Netherlands), (Anti-Gapdh (#sc6215, Santa Cruz, Heidelberg, Germany),
Anti-DCN (#AF143 and #AF1060, R&D, Abingdon, UK), Anti-BGN (#ENH020, Kerafast,
Boston, USA), Anti-Sp7 (#ab22552, Abcam, Cambridge, UK), Anti-Spp1 (#MPIIIB10, DSHB,
Iowa, USA), Anti-Dmp1 (#AF4386, R&D, Abingdon, UK). For immunofluorescence on cells
we used the following antibodies: anti-decorin (#14667 Proteintech) anti-GM130 (clone 35,
BD Biosciences), anti-VSV-tag (clone P5D4, Sigma). Sheep and rabbit GORAB antibodies
were raised against GST-tagged N-terminal (1–130 aa) and C-terminal (301–369 aa) regions of
human GORAB respectively and affinity purified against these same proteins. Serum was pre-
cleared against GST before affinity purification on immunogen. Antibodies against TGN46
were provided by Dr S. Ponnambalam (University of Leeds, United Kingdom), while GD3A12
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anti-DS antibody was a kind gift of Dr Toin van Kuppevelt (Radboud University Nijmegen
Medical Center, The Netherlands)[26]. For immunohistochemistry, Vectastain elite ABC kit
(Vector Laboratories, Burlingame, CA) was used for signal detection. For immunofluores-
cence on sections, the Tyramide signal amplification system (Perkin Elmer, Baesweiler, Ger-
many) was used for signal development.
In vitro differentiation of calvarial osteoblasts
Calvarial osteoblast progenitor cells were isolated as previously described [62]. Cells were
seeded on 6-well plates in Alpha-MEM (Lonza, Basel, Switzerland) containing 10% fetal calf
serum (FCS; Gibco, Life Technologies, Carlsbad, California, USA) as well as Pen/Strep (100U/
mL, Lonza) and 2 mM ultra-glutamine (Lonza). Osteogenic differentiation was induced by
with 50 μM L-ascorbate-2-phosphate and 10 mM beta-glycerophosphate.
Alkaline phosphatase and matrix mineralization assays
Quantitative AP and matrix mineralization assays were performed as previously described
[62]. Shortly, AP activity was determined by homogenizing 3 replicates separately in ALP-
buffer1 (0.1 M Glycine; 1% NP-40; 1 mM MgCl2; 1 mM ZnCl2). After the addition of 1 vol-
ume of ALP-buffer2 (5 mM p-nitrophenyl phosphate [p-NPP], 0.1 M glycine, pH 9.6, 1 mM
MgCl2, and 1 mM ZnCl2), reactions were incubated at 37˚C for 30 min and stopped by addi-
tion of 1 M NaOH. The amount of p-NP released from the substrate p-NPP was recorded at
405 nm. AP activity is given as unit of absorption / μg protein / 30 min. Cells were fixed with
4% PFA prior to staining with Alizarin Red.
In vitroTGF-ß reporter cell assay
Skin biopsies from E18.5 GorabNull embryos were homogenized in liquid nitrogen and soluble
protein was extracted with 1X PBS, 1X complete protease inhibitor cocktail (Roche, Mann-
heim, Germany) for 16h at 4˚C with agitation. Protein content of the lysates was then quanti-
tated by BCA assay (Thermo Fisher, Dreieich, Germany) and 500μg of protein (either heat
activated at 80˚C for 10min for the total TGF-ß or without activation) was added to Plasmino-
gen activator inhibitor-1–luciferase reporter mink lung epithelial cells (gift from Prof. Petra
Knaus, Freie Universita¨t, Berlin, Germany) and incubated for 16h. The lysates of the reporter
cells were than collected for the luciferase activity using the Dual luciferase reporter system
(Promega, Mannheim, Germany) and the amount of TGF-ß in skin lysates was quantitated by
comparing with reporter cells treated with known amounts of recombinant TGF-ß
(eBioscience, Frankfurt, Germany).
Electrophoretic analysis of collagen secretion
Post-confluent human skin fibroblast were labelled for 18 h with 10μCi/ml L-[2,3,4,5-3H]-Pro-
line in medium containing 0.15mM ascorbic acid. The secreted collagen in the medium was
precipitated with 25% ammonium sulfate and then resuspended in 50mM Tris, 150mM NaCl
pH7.5, which was then subjected to pepsin digestion (50μg/ml) at 4˚C for 16h. The digested
samples were then lyophilized and separated by SDS-PAGE and the labelled collagen chains
were detected by fluorography.
Analysis of cell-derived ECM
WT and GO human skin fibroblasts were seeded into 6-well plates and cultured for 8 days
under standard conditions with media change on day 4. After 8 days cells were washed twice
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with PBS and the ECM was extracted by incubation with 300 μL of urea buffer (6 M urea, 25
mM dithiothretol (DTT) in 25 mM ammonium bicarbonate) for 10 min at RT. ECM samples
were then subjected to SDS-PAGE and decorin was analyzed by WB.
Analysis of decorin in MEFs
WT and GO MEFs were seeded into 6-well plates and cultured under standard conditions
until they reached confluency. Cells were then stimulated to produce ECM components by
incubation in fibroblast-specific serum-free medium (Lifeline Cell Technology) for 7 days.
Cells were then lysed, samples were subjected to SDS-PAGE and decorin was analyzed by
western blotting.
Analysis of intra-Golgi decorin and GAG levels
WT and GO fibroblasts were seeded as a co-culture on glass coverslips to ensure fair compari-
son of signal intensities between controls and mutant cells and to exclude the influence of
extrinsic factors. The cells were grown till 90% confluency. Cells were washed twice with PBS,
fixed with 3% (wt/vol) PFA in PBS for 25 min at RT. Cells were then washed with PBS and the
excess of paraformaldehyde was quenched with glycine. The cells were permeabilized by 4 min
incubation in 0.1% (wt/vol) Triton X-100 in PBS. Cells were incubated with primary antibody
diluted in PBS for 1 hour at RT and incubated three times with PBS for 5 min. Then coverslips
were incubated for 1 h with secondary antibody diluted in PBS and incubated three times with
PBS for 5 min and twice in ddH20 for 5 min. In case of the GD3A12 antibody detecting derma-
tan sulfate, the primary antibody was recognized by P5D4 clonal antibody against VSV-tag
prior to incubation with fluorescently-conjugated secondary antibody. Coverslips were dried
before mounting in Mowiol 4–88 and images were acquired on a Ti inverted microscope
(Nikon) using a x60/1.4 Plan Apo objective, Proscan II motorized stage (Prior Scientific) and
R6 CCD camera (QImaging). A SpectraX LED light engine (Lumencore), quad dichroic (Sem-
rock) and motorized emission filter wheel (Prior Scientific) with single bandpass filters for
FITC, TRITC and Cy5 (Semrock) were used to collect image sequences at each position in
the tile. Images were acquired and then aligned and stitched using NIS Elements software
(Nikon). These stitched images were then exported as a single TIFF image for further process-
ing in Fiji software [63]. The amount of intra-Golgi decorin and GAG was measured by com-
paring fluorescence intensity levels with reference to the Golgi markers GM130 and TGN46.
GORAB staining was employed to discriminate between WT and GO fibroblasts.
Gene expression analysis
RNA isolation from cultured cells. Total RNA was isolated from cultured skin fibroblasts
or from osteoblast cultures at time 0 (i.er., without stimulation), 3 days, 6 days, and 12 days
using TRIzol reagent (Life Technologies, Darmstadt, Germany). RNA integrity was confirmed
using the RNA 6000 Nano Kit on the 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
USA).
RNA isolation from cortical bone tissue. For isolation of femoral cortical bone epiphyses
were cut off, and bone marrow was flushed out. The hollow bone shaft was then digested twice
with 0.2% collagenase (Sigma-Aldrich, Munich, Germany) in isolation buffer (70mM NaCl,
10mM NaHCO3, 60mM sorbitol, 30mM KCl, 3mM K2HPO4, 1mM CaCl2, 0.1% bovine serum
albumin, 0.5% glucose, 25 mM HEPES) at 37˚C for 20 minutes each under vigorous shaking.
The cleared bone shaft was frozen in liquid nitrogen and then homogenized with pestle and
mortar. RNA was extracted from the homogenized tissue with TRIzol reagent (Life Technolo-
gies, Darmstadt, Germany).
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Microarray expression analysis. Femoral and tibial cortical bone mRNA from 4 week old
control and GorabPrx1 mutants (N = 3) was hybridized on an MG ST 1.0 microarray (Affyme-
trix, High Wycombe, United Kingdom). The raw image files were converted to cel files using
the dChip software. The data were subjected to a quality assurance analysis using the sim-
pleaffy package of Bioconductor. Normalization and summarization of the probe set data were
conducted using the gcrma package.
RNA-sequencing and analysis. For library preparation the TruSeq RNA Sample Prep Kit
was used and after cluster generation by the TruSeq PE Cluster Kit 75bp paired-end sequenc-
ing occurred on an HiSeq 2000 machine (Illumina, San Diego, USA). We analyzed the differ-
ential gene expression of the RNA-seq data at the different time points by the DESeq2 package,
where the raw count of the reads is normalized taking into account the sample size factor and
for further sources of technical biases such as differing dependence on GC content or the gene
length. For the comparison of the aligned reads across samples, we used Bioconductor package
DESeq2 which uses a generalized linear model (GLM) of the negative binomial distribution of
the normalized gene counts.
Quantitative PCR. RNA was reverse-transcribed using the RevertAid H Minus First
Strand cDNA Synthesis Kit (Life Technologies, Darmstadt, Germany) with random hexamer
primers. Quantitative PCR was performed with SYBR green (Life Technologies, Darmstadt,
Germany) on ABI Prism 7500 (Life Technologies, Darmstadt, Germany). Expression levels
were normalized to Gapdh expression. Primer sequences are given in S2 Table.
Statistical analysis
All values are shown as mean ± SD. Data were analyzed with unpaired-two-tailed Student’s t
test. Microarray data was analyzed by One-Way-ANOVA. A p-value smaller than 0.05 was con-
sidered statistically significant. In all figures,  p-value< 0.05,  p-value< 0.01,  p-value<
0.001, n.s. = not significant
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S1 Fig. Animal models used in this study. (A) Schematic illustration of the position of the
genetrap cassette (β-geo) within intron 1 of the Gorab locus in XG183 GorabNull mouse. (B)
Quantitative PCR showing successful inactivation of Gorab in GorabNull mouse skin (N = 3).
(C) Strategy for generation of Gorabflox conditional mice. (D) Detection of targeted Gorab
allele by Southern blot.
(PDF)
S2 Fig. Characterization of lethal GorabNull mice. (A) Pictures of a newborn (P0) GorabNull
mouse which died shortly after birth illustrating no significant morphological changes and no
cutis laxa phenotype. (B) Hematoxylin/eosine stained skin section from P0 GorabNull mouse
mutant and control showing no significant alteration. Scale bar = 50μm. (C) Lung sections
from P0 GorabNull mutant and control after breathing stained by hematoxylin/eosine showing
collapsed alveoli and reduced septation. (D) Lung sections from E18.5 GorabNull and control
embryo before breathing stained by hematoxylin/eosine or toluidine, also showing reduced
airspace thus underlining that the phenotype is not due to an inability for respiratory excur-
sions. Scale bar = 200μm.
(PDF)
S3 Fig. Characterization of bone phenotype in GorabNull mouse embryos. (A) Alizarin red/
alcian blue staining of E18.5 GorabNull skeleton showing no observable difference in the rib
cage and forelimb, but a slightly smaller mandibula. (B) μCT reconstructed E18.5 GorabNull
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mouse skull showing enlarged fontanels. (C) μCT reconstructed image of the tibia midshaft of
E18.5 GorabNull embryo in axial orientation. Apart from a slightly shorter diameter there is no
significant difference in the developing, still highly porous cortical bone between mutant and
control. (D) Representative sections of proximal tibia from E18.5 control and GorabNull ani-
mals stained with Goldner trichrome/ von Kossa. Scale bar = 200μm. (E) Histomorphometric
analysis of E18.5 control and GorabNull tibia trabecular bone (N = 3). (F) Expression of osteo-
cyte markers in bone of P0 GorabNull mutants (N = 3) already showing upregulation of Dmp1
and downregulation of Sost, indicating a delay in osteocyte differentiation. (G) Alkaline phos-
phatase (AP) and alizarin red staining after 7 and 21 days of osteogenic differentiation of
primary calvarial osteoblasts from E18.5 GorabNull mutants, respectively. (H) Alkaline phos-
phatase (AP) enzymatic activity of primary calvarial osteoblast of E18.5 GorabNull comparing
to control after 4 days (Control vs. GorabNull, N = 11 vs. 5) and 7 days Control vs GorabNull,
N = 13 vs. 6) of osteogenic differentiation.
(PDF)
S4 Fig. Gorab expression during normal osteoblast differentiation and its loss in the dif-
ferent conditional mouse models. (A) Expression levels of Gorab in comparison to several
transcription factors and ECM proteins in differentiating calvarial osteoblasts from three inde-
pendent experiments with four calvariae each. Note peak of Gorab expression at day 6 of dif-
ferentiation together with Col1a1 and Dcn while the late osteoblast marker Dmp1 is only
significantly expressed at day 12. Prrx1 (encoding Prx1) and Runx2 expression are high at the
beginning of osteogenic differentiation at day 0. (B) qPCR analysis of Gorab expression in tibia
diaphysis of 12 week old control (N = 3), GorabPrx1 (N = 3), GorabRunx2 (N = 3) and GorabDmp1
(N = 3) mice demonstrating similar efficiencies for cre-induced inactivation.
(PDF)
S5 Fig. microCT analysis of different Gorab mutants. microCT analysis of trabecular bone
volume fraction (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabec-
ular separation (Tb.Sp) of (A) tibia and (B) sixth lumbar vertebrae of twelve week old Gor-
abPrx1 (N = 15), GorabRunx2 (N = 5), GorabDmp1 (N = 8) and corresponding littermate control
animals (N = 14, N = 5, N = 9 respectively).
(PDF)
S6 Fig. Histomorphometric analysis of a bone biopsy from a GO patient. (A) Von Kossa/
Van Gieson staining and (B) Goldner trichrome staining of bone biopsy from a nine year old
GO patient. (C) Histomorphometric analysis showing strong reduction of trabecular bone vol-
ume fraction (BV/TV), accumulation of osteoid (OV/TV and OS/BS) and increase in osteo-
blast (N.Ob/B.Pm) and osteocyte number (N.Ot/trab B.Pm and N.Ot/cort B.Pm) in the GO
patient similar to GorabPrx1 mice.
(PDF)
S7 Fig. Characterization of collagen secretion from skin fibroblasts from GO patients and
GAG content in E18.5 GorabNull mice skin. (A) Electrophoresis of 3H labeled collagen from
control and GO fibroblast culture (N = 3). Note comparable secretion levels. (B) Pulse-chase
experiment for global protein secretion by cultured control and GO fibroblasts (N = 3) show-
ing no significant difference. (C) Quantitation of heparan sulfate and hyaluronan in skin, carti-
lage, lung and brain of E18.5 GorabNull mice (N = 3–4). (D) Immunoblot of biglycan in lysates
from mouse embryonic fibroblasts. Note migration of glycanated band around 100 kDa and of
the core protein at around 45 kDa. Mutant cells show a stronger core protein band and a
smear of incompletely glycanated protein species. (E, F) Immunoblot of decorin (E) and bigly-
can (F) in skin lysates from E18.5 GorabNull mice with and without chondroitinase ABC
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digestion (ABC). Note increased detection of the core protein after chondroitinase ABC diges-
tion. The fully glycanated bands are not clearly detected, probably as a consequence of the spe-
cial sample preparation necessary for the enzyme incubation. (G) qPCR analysis of biglycan
and decorin expression in skin of E18.5 GorabNull embryo (N = 4) and (H) femur diaphysis
from four week old GorabPrx1 mice (N = 6).
(PDF)
S1 Table. Expression profiling in cortical bone from four week old GorabPrx1 mutants and
controls.
(XLSX)
S2 Table. Primers used for quantitative PCR analysis.
(XLSX)
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